A Review on Recent Technologies, Trending Methods and Clinical Trial of PIPAC

Abstract

In the last few years, intraperitoneal (IP) chemotherapy has increased expectations for the treatment of peritoneal diseases of digestive and gynecological cancers. In peritoneal carcinomatosis patients, intraperitoneal drugs can be given, repeated installation, either as an intraoperative chemoperfusion or as a substance that enhances the immune system's response to the presence of an antigencan show a well-established therapeutic effect. The ability of intraperitoneal (IP) drugs to enter the tumour stroma and meet their cellular target determines their efficacy. Drug penetration after intraperitoneal (IP) distribution is believed to be limited to a few millimeters. Therefore, peritoneal metastases (PM) patients now have a single mildly successful treatment. A new specific area treatment approach to peritoneal metastases (PM) was recently initialized by combining laparoscopy for aerosol delivery of anticancer drugs intraperitoneally. The recently used intraperitoneal chemotherapeutic approach is Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC), which is a promising way to administer drugs in a minimally invasive and healthy manner. This review addresses the anatomy of intraperitoneal, fundamental processes regulating aerosol particle transfer and peritoneal deposition, as well as the logic, and widely used technologies for therapeutic IP nebulization, physical parameters, recent clinical trials, PIPAC based recent methods and evaluations.